Clinical trials
Brain Injuries, Traumatic trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 4 |
| Unknown status | 4 |
| Recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiden University Medical Center | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Amsterdam UMC, location VUmc | 1 |
| Banyan Biomarkers, Inc | 1 |
| Erasmus Medical Center | 1 |
| Fondazione Don Carlo Gnocchi ETS | 1 |
| Maastricht University Medical Center | 1 |
| Marsh Königs | 1 |
| Pfizer | 1 |
| UMC Utrecht | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Injuries, Traumatic | 14 |
| Stroke | 3 |
| Brain Injuries | 2 |
| Craniocerebral Trauma | 2 |
| Intracranial Hemorrhages | 2 |
| Subarachnoid Hemorrhage | 2 |
| Amyotrophic Lateral Sclerosis | 1 |
| Angioedemas, Hereditary | 1 |
| Brain Stem Infarctions | 1 |
| Dwarfism, Pituitary | 1 |
Trials
Showing 26 to 14 of 14. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.